If you have been reading about visceral adipose tissue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | 2 to 8 °C | Refrigerated, protected from light |
| Appearance | White to off-white powder | Lyophilized cake in a single-use vial |
| Solubility | Soluble in water | Yields a clear solution after reconstitution |
| Identity method | Electrospray mass spectrometry | Confirms the expected molecular mass |
| Purity method | Reversed-phase HPLC | Reports main peak against related substances |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
=== Nonprofit organizations === In the 2020s, several nonprofit organizations have emerged in the U.S. and Europe to focus on AI safety and related public policies, including the Alliance for Secure AI, Future of Life Institute, and Public First Action. Such groups often function as Silicon Valley watchdogs and advocate for specific federal, state, or local regulations. They also compete with industry groups such as Leading the Future, which advocate for the deregulation of AI companies.
==== Enzymes used ==== A commonly used protease mixture is "Flavourzyme", extracted from Aspergillus oryzae, the mold used for soy sauce production. This mixture contains both endo- and exo-peptidases. The endopeptidase Alcalase may also be used, but without an exopeptidase it tends to generate a bitter flavor. As a result, it should be used with a companion exopeptidase. A commercial exopeptidase produced for this purpose is "Protana Prime", a mixture with both leucine aminopeptidase and carboxypeptidase D activity. Beyond proteolysis, the amount of umami taste can also be increased by adding a glutaminase, which converts glutamine to glutamate. Commercial options include "Protana Boost" and others.
== Chemical analysis == Analysis of monoglycosylceramides can be done by high-resolution thin-layer chromatography, high-performance liquid chromatography (HPLC), and mass spectrometry. Reversed-phase HPLC is now the standard method for separation of molecular species, often after benzoylation, enabling lipids to be detected by UV spectrophotometry.
== Signs and symptoms == The bite of a Sydney funnel web spider is at first painful, due to the large fangs and acidic pH of the venom. If there is no immediate treatment symptoms may arise beginning ten minutes after the bite. Hypertension may occur, which is often followed by a prolonged hypotension and circulatory failure. Other symptoms include dyspnea and ultimately respiratory failure, generalized skeletal muscle fasciculation, salivation, lachrymation, sweating, nausea, vomiting, diarrhoea, pulmonary edema and pain. The progress of the envenomation is precisely studied in primates, which symptoms are very similar to those of humans. In the first 25 minutes after envenomation disturbances in respiration occur, which gradually become worse. Some monkeys required artificial ventilation. Initially, the blood pressure decreased, but then quickly rose, after which the blood pressure gradually declined. After 40–100 minutes severe hypotension occurred. Lachrymation started after 6–15 minutes and was followed by salivation. These symptoms were most severe during 15–35 minutes after envenomation. Skeletal muscle fasciculation started after 8–10 minutes and reached its peak between 20 and 45 minutes. It was accompanied with an increase in body temperature. Envenomation with the male venom produced mostly the same symptoms, although the onset of the symptoms was a little delayed. The female venom also produces the same symptoms, but far less severe.
Bush released his memoirs, Decision Points, on November 9, 2010. During a pre-release appearance promoting the book, Bush said he considered his biggest accomplishment to be keeping "the country safe amid a real danger", and his greatest failure to be his inability to secure the passage of Social Security reform. He also made news defending his administration's enhanced interrogation techniques, specifically the waterboarding of Khalid Sheikh Mohammed, saying, "I'd do it again to save lives." In 2012, he wrote the foreword to The 4% Solution: Unleashing the Economic Growth America Needs, an economics book published by the George W. Bush Presidential Center. He also presented the book at the Parkland Memorial Hospital in Dallas, Texas. Bush did not physically appear in that year's Republican National Convention (where Mitt Romney obtained the party's nomination for president), instead appearing in a videotape, in which he –alongside his father and immediate family– explained his reasons for supporting Romney. Bush appeared on NBC's The Tonight Show with Jay Leno on November 19, 2013, along with his wife Laura. When asked by Leno why he does not comment publicly about the Obama administration, Bush said: "I don't think it's good for the country to have a former president criticize his successor." Despite this statement, Bush vocally disagreed with Obama's withdrawal of U.S. troops from Iraq in 2011, calling it a "strategic blunder". In December, Bush traveled with President Obama to the memorial service of South African president and civil rights leader Nelson Mandela.
Sources: en.wikipedia.org
== Constitutionality in the United States == In 2006, the Supreme Court ruled in Hill v. McDonough that death-row inmates in the United States could challenge the constitutionality of states' lethal injection procedures through a federal civil rights lawsuit. Since then, numerous death-row inmates have brought such challenges in the lower courts, claiming that lethal injection as practiced violates the ban on "cruel and unusual punishment" found in the Eighth Amendment to the United States Constitution. Lower courts evaluating these challenges have reached opposing conclusions. For example, courts have found that lethal injection as practiced in California, Florida, and Tennessee is unconstitutional. Other courts have found that lethal injection as practiced in Missouri, Arizona, and Oklahoma is constitutionally acceptable. As of 2014, California has nearly 750 prisoners condemned to death by lethal injection despite the moratorium imposed when, in 2006 a federal court found California's lethal injection procedures to be unconstitutional. A newer lethal injection facility has been constructed at San Quentin State Prison which cost over $800,000, but it has yet to be used because a state court found that the California Department of Corrections and Rehabilitation violated the California Administrative Procedure Act by attempting to prevent public oversight when new injection procedures were being created. On September 25, 2007, the United States Supreme Court agreed to hear a lethal-injection challenge arising from Kentucky, Baze v. Rees.
Per Baseball Reference, Bagwell's 79.6 Wins Above Replacement (WAR) ranks sixth-most all-time among first basemen, trailing only Lou Gehrig, Albert Pujols, Jimmie Foxx, Cap Anson, and Roger Connor. He spent the first nine seasons of his career (1991–99) playing home games at the Astrodome, notorious for its reputation as the toughest park in which to hit when baseball was still played there. However, during those nine years, his production at home was nearly identical to his production on the road. In that same period of time, his 160 OPS+ was fourth behind Bonds, McGwire, and Frank Thomas; his 56.7 WAR was third behind Bonds and Ken Griffey Jr. From 1994 to 2000, a span including his age-26 through age-32 seasons, he averaged 41 home runs and 41 doubles per 162 games while batting .309, .433 OBP, and .593 SLG for a 167 OPS+. Over his career, Bagwell batted at least .300 six times, amassed a 1.000 OPS five times, collected at least 30 home runs eight times, 100 RBI eight times, 100 runs scored nine times, and 100 walks seven times. He is the only player in history to achieve six consecutive seasons (1996–2001) with each of 30 home runs, 100 RBI, 100 runs scored, and 100 walks. Bagwell had seven seasons with 30 home runs and 100 walks; the only players with more are Gehrig, Ruth, Williams, Jim Thome, and Thomas. Bagwell is one of 12 players in MLB history to hit at 400 home runs and attain a career on-base percentage of at least .400. The only National League first baseman to reach the 30–30 club, he is the only first baseman in history to do it twice.
Founding the Biomedical Engineering Society's Diversity Committee. Co-founding KEYs (Keys to Empowering Youth), a program that brings middle-school girls to visit high-tech labs to encourage their interest in science and technology. Chairing the Institute of Medical Engineering and Science Diversity Committee at MIT. Serving on the Faculty Gender Equity Committee at the MIT School of Engineering and advising the MIT Society of Women Engineers. Bhatia's advocacy and groundbreaking work have made her a public figure, featured in diverse media. She has been named one of Fast Company's Most Creative People (2014) and a Foreign Policy's leading global thinker. Her inspiring story has been featured on TV Nova Science Now, in the film Picture a Scientist, and in various books and podcasts. She's even been rendered as a LEGO minifigure and recognized among Vogue India's Incredible Women, showcasing her broad impact and visibility. Bhatia and her over 85 trainees have contributed to more than 230 peer-reviewed scientific papers and more than 65 issued or pending patents over twenty years. As of 2025, Bhatia has launched 8 biotechnology companies at the intersection of medicine and miniaturization. About three-quarter of her former postdoctoral trainees are current academic faculty members (half of which are already tenured), while a quarter of her 39 Ph.D. graduates are academic faculty members and another quarter hold Director or C-suite roles in biotech and pharma companies.
== Further reading == Collins R (2017). "Lowering Restrictions on Performance Enhancing Drugs in Elite Sports". Inquiries Journal. 9 (3). Retrieved 7 July 2017. Franke WW, Berendonk B (July 1997). "Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government". Clinical Chemistry. 43 (7): 1262–79. doi:10.1093/clinchem/43.7.1262. PMID 9216474. Mottram, David (2005); Drugs in Sport, Routledge. ISBN 978-0-415-37564-1. Murray, Thomas H. (2008); "Sports Enhancement", in From Birth to Death and Bench to Clinic: The Hastings Center Bioethics Briefing Book for Journalists, Policymakers, and Campaigns. Pope J, Harrison G, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S (2014). "Adverse health consequences of performance-enhancing drugs: An endocrine society scientific statement". Endocrine Reviews. 35 (3): 341–375. doi:10.1210/er.2013-1058. PMC 4026349. PMID 24423981. Waddington and Smith (2008); An Introduction to Drugs in Sport, Routledge. ISBN 978-0-415-43125-5. Collins R (2017). "Lowering Restrictions on Performance Enhancing Drugs in Elite Sports". Inquiries Journal. 9 (3). Retrieved 7 July 2017. Toby M (2024). The History of Performance-Enhancing Drugs In Thoroughbred Racing. University of Kentucky Press. ISBN 9780813197975.
=== Fixed election dates === Ford's government announced a proposal on October 27, 2025, to eliminate fixed election dates as part of a series of changes to provincial election law in order to "return Ontario to an electoral process that served our province well... prior to the imposition of American-style fixed election dates." The bill removing fixed election dates received royal assent and went into effect on November 27.
Sources: en.wikipedia.org
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.
Mass spectrometry gives the molecular weight, and mapping after digestion gives sequence coverage. Reversed-phase chromatography then supplies a purity profile.
Different groups report purity with different methods and thresholds, and full validation data are seldom published. Direct comparison of activity across batches therefore stays uncertain.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.